DiscoverBlood & CancerNews | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas
News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas

News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas

Update: 2020-12-01
Share

Description

Blood & Cancer News Stories: 

  1. Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest: https://bit.ly/2JlP2FN
  2. HCC rates slow in cities, continue to climb in rural areas: https://bit.ly/2Jx6Ux1
  3. Risk factors for severe immune-related AEs identified: https://bit.ly/3fO6Fd8

Contact Blood & Cancer at podcasts@mdedge.com

 

Comments 
In Channel
loading
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas

News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas

Medscape Professional Network